Chat with us, powered by LiveChat

Overview

Expert & agile partner offering CDMO services

 

Skyepharma is the oral business Unit of the Vectura Group of Companies (LSE: VEC), an industry-leading device and formulation company specialized in airways disease : www.vectura.com

Mission

Skyepharma’s mission is to provide product development, manufacturing and packaging services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships.

 

Vision

Solving healthcare industry complexity.

Overview

Expertise and Agility

Skyepharma is deeply committed in performance management and value creation for its clients. Service offering is continuously improved to propose state-of-the-art global development, manufacturing and packaging services.

Our partners can rely on our agility and scientific expertise resulting in accelerated time to market and maximized value across all pharmaceutical lifecycle stages.

Who we are FACTS & FIGURES

Identity

Activities

Global Market

Certifications

  • 1996: Creation of Skyepharma
  • 30 years of experience in oral solid dosage forms
  • More than 110 employees including ¼ in development department
  • Located near Lyon, France
  • Fully integrated CDMO since 2016
  • Pharmaceutical Industry
  • Food supplement Industry
  • Products commercialized in US, EU, Brazil and Asia
  • 40% of products exported to the US market
  • March 2019 : 1st batch serialized and aggregated for US market
  • EU GMP certified facilities
  • FDA approved since 1998. Last inspection in september 2019
  • ANVISA approved since 2013
  • Registered at Korean MFDS since 2013

Available capacity for your projects

1400

Millions tablets per year

150

Millions capsules per year

40

Millions blisters per year

10

Millions Bottles per year